Corporate Overview
Cytonics is a clinical-stage biotechnology company developing CYT‑108, a genetically engineered variant of Alpha-2-Macroglobulin (A2M) designed to treat osteoarthritis (OA) by repair by blocking the enzymes that break down cartilage, stimulating cartilage cells to multiply, and increasing the production of essential building blocks like collagen and aggrecan that give cartilage its strength and cushion.
Our first-generation APIC™ therapy has treated over 10,000 patients, clinically validating A2M as a viable, disease-modifying therapy for OA. APIC™’s clinical and commercial success uniquely de-risks the development of our next-generation A2M-based therapy for OA: CYT-108.
Backed by over 20 years of research and fortified by 25 international patents, CYT‑108 is poised to enter Phase 2 clinical trials as a potent, scalable biologic with the potential to cure OA once and for all. Unlike traditional biotechs reliant on VC and Big Pharma, we’ve raised over $25 million from 7,000+ individual investors via equity crowdfunding – maintaining strategic independence, capital efficiency, and a clean, founder-aligned cap table.
20+ Years of
Research
Recombinant A2M Platform
10,000+ Patients Treated with APIC
7,000+ Grassroots Investors
$25M+ Raised via
Crowdfunding
Phase 1 Trial
Complete
Targeting $500B Global
OA Market
Press Releases
Milestones
Investor Presentation
Investor Presentation – From scalpel to startup: a surgeon’s discovery. A biotech rebellion.
This investor deck lays out how we’re developing the first disease-modifying therapy for osteoarthritis, how we’ve raised over $15M from 6,000+ grassroots investors, and why our recombinant A2M platform could unlock a $500B market opportunity. Inside you’ll find:
- The science behind A2M
- CYT-108 clinical data and preclinical results
- IP strategy and global patent coverage
- Capital strategy and exit scenarios
- Our plan to succeed where Big Pharma has failed
Intellectual Property
A Globally Protected Platform Built to Last
Cytonics has built a robust and multi-layered intellectual property portfolio around its A2M therapeutic platform targeting osteoarthritis and other inflammatory conditions. Our IP strategy protects not only CYT-108, our lead recombinant A2M biologic, but also the underlying protein engineering methods, manufacturing processes, and broader therapeutic applications of our A2M-based technologies.
Protecting a Platform, Not Just a Product
Cytonics’ IP extends beyond osteoarthritis, with patent claims supporting expansion into other protease-driven and inflammatory conditions, including rheumatoid arthritis, inflammatory lung conditions, and even metastatic cancers.
This broad coverage positions Cytonics’ A2M-thjerapies as a platform technology, with the ability to scale and freedom to operate across multiple disease indications and delivery modalities, while maintaining long-term exclusivity via an aggressive patent prosecution strategy (via Wilson Sonsini Goodrich & Rosati’s intellectual property counsel)
Strategic partners and prospective investors may contact us for a full list of patents and to access our dataroom.
A Multi-Layered Approach to IP Protection
Cytonics holds 25 international patents and multiple pending applications across key global marketed: United States, European Union, Canada, Australia, Japan, United Kingdom, Germany, and France.
These patents encompass:
- Composition of matter for recombinant A2M variants, including CYT-108
- Methods of use for the treatment of osteoarthritis and other inflammatory musculoskeletal conditions
- Process development for the selective enrichment of endogenous A2M
Our IP estate provides protection through at least 2040, with ongoing filings that reflect insights gained from our preclinical studies and Phase 1 clinical trial.
